## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Blake John T						2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [ LIFE ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last)	(Last) (First) (Middle) 3545 JOHN HOPKINS COURT, SUITE 250				3. Date of Earliest Transaction (Month/Day/Year) 09/13/2016									x	Office below	er (give title /)	ent	Other ( below)		
3545 JO	HN HOPKI	NS COURT, SUI											Vice President, Finance							
(Street)	4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)									
SAN DIEGO CA 92121														X Form filed by One Reporting Person						
(City)	(S <sup>i</sup>	tate) (		-										Form filed by More than One Reporting Person				orting		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) Date (Month/Day						Execution Date,			Transaction Dispo Code (Instr. and 5			rities Acq ed Of (D)		4 Securiti Benefic Owned		ties For cially (D) Ind		rect (I)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amoun	t (A) or (D) Pr		e	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transact Code (In 8)	tion of			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of Deri Sec	rice ivative urity tr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		
					Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amoun or Numbe of Shares							
Employee Stock Option (right to buy)	\$3.06	09/13/2016			A		19,000		(1)	09	/13/2026	Common Stock	19,00	0 \$	0.00	19,000		D		

#### Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning October 13, 2016, such that this option will be fully exercisable on September 13, 2020. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.

Remarks:

### Nancy D. Krueger, attorney-infact 09/15/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.